Literature DB >> 7559726

Molecular targets in the National Cancer Institute drug screen.

S E Bates1, A T Fojo, J N Weinstein, T G Myers, M Alvarez, K D Pauli, B A Chabner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7559726     DOI： 10.1007/bf01197759

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  17 in total

1.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

2.  Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data.

Authors:  K D Paull; C M Lin; L Malspeis; E Hamel
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

3.  Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.

Authors:  T Utsugi; S Demuth; N Hanna
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

4.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.

Authors:  J S Lee; K Paull; M Alvarez; C Hose; A Monks; M Grever; A T Fojo; S E Bates
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

5.  Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study.

Authors:  F S Morrison; R Benjamin; M Amare; J J Costanzi; K Hussein; D H Ryan; S Balcerzak; O J Pendleton
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Intensive treatment of acute leukemia in adults 70 years of age and older.

Authors:  R S Walters; H M Kantarjian; M J Keating; E H Estey; K B McCredie; E J Freireich
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

7.  Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents.

Authors:  W W van Osdol; T G Myers; K D Paull; K W Kohn; J N Weinstein
Journal:  J Natl Cancer Inst       Date:  1994-12-21       Impact factor: 13.506

8.  Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS.

Authors:  J N Weinstein; T Myers; J Buolamwini; K Raghavan; W van Osdol; J Licht; V N Viswanadhan; K W Kohn; L V Rubinstein; A D Koutsoukos
Journal:  Stem Cells       Date:  1994-01       Impact factor: 6.277

9.  A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia.

Authors:  M J Keating; T L Smith; K B McCredie; G P Bodey; E M Hersh; J U Gutterman; E Gehan; E J Freireich
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

10.  Neural computing in cancer drug development: predicting mechanism of action.

Authors:  J N Weinstein; K W Kohn; M R Grever; V N Viswanadhan; L V Rubinstein; A P Monks; D A Scudiero; L Welch; A D Koutsoukos; A J Chiausa
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728
View more
  9 in total

1.  Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Authors:  Kyu Kwang Kim; Thilo S Lange; Rakesh K Singh; Laurent Brard
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

2.  Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells.

Authors:  Jae K Lee; Kimberly J Bussey; Fuad G Gwadry; William Reinhold; Gregory Riddick; Sandra L Pelletier; Satoshi Nishizuka; Gergely Szakacs; Jean-Phillipe Annereau; Uma Shankavaram; Samir Lababidi; Lawrence H Smith; Michael M Gottesman; John N Weinstein
Journal:  Genome Biol       Date:  2003-11-25       Impact factor: 13.583

3.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

Authors:  V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S Gutkind
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

4.  Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.

Authors:  Gurmeet Kaur; Melinda Hollingshead; Susan Holbeck; Vesna Schauer-Vukasinović; Richard F Camalier; Alexander Dömling; Seema Agarwal
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

5.  A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.

Authors:  Bashir Lawal; Wen-Cheng Lo; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Harshita Khedkar; Alexander Th Wu; Hsu-Shan Huang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  High throughput ratio imaging to profile caspase activity: potential application in multiparameter high content apoptosis analysis and drug screening.

Authors:  Jeena Joseph; Mahendra Seervi; Praveen K Sobhan; Santhoshkumar Thankayyan Retnabai
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

7.  SAR of Novel 3-Arylisoquinolinones: meta-Substitution on the Aryl Ring Dramatically Enhances Antiproliferative Activity through Binding to Microtubules.

Authors:  Mai A Elhemely; Asma A Belgath; Sherihan El-Sayed; Kepa K Burusco; Manikandan Kadirvel; Annalisa Tirella; Katherine Finegan; Richard A Bryce; Ian J Stratford; Sally Freeman
Journal:  J Med Chem       Date:  2022-03-15       Impact factor: 7.446

8.  Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines.

Authors:  Bashir Lawal; Yen-Lin Liu; Ntlotlang Mokgautsi; Harshita Khedkar; Maryam Rachmawati Sumitra; Alexander T H Wu; Hsu-Shan Huang
Journal:  Biomedicines       Date:  2021-01-19

9.  HLA class I and II genotype of the NCI-60 cell lines.

Authors:  Sharon Adams; Fu-Meei Robbins; Deborah Chen; Devika Wagage; Susan L Holbeck; Herbert C Morse; David Stroncek; Francesco M Marincola
Journal:  J Transl Med       Date:  2005-03-04       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.